JP Morgan Chase
MLTX icon

JP Morgan Chase’s MoonLake Immunotherapeutics MLTX Stock Holding History

JP Morgan Chase’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,800
Closed -$1.75M – 7607
2024
Q1 		$1.75M Buy
34,800
+27,800
+397% +$1.51M ﹤0.01% 3946
2023
Q4 		$423K Buy
+7,000
New +$361K ﹤0.01% 4903

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's MLTX Position: Q2 2026 in Review

JP Morgan Chase increased its MoonLake Immunotherapeutics (MLTX) stake by 27% in Q2 2026, buying an estimated $5.4M and bringing the position to 1,386,422 shares worth $27.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1946.

JP Morgan Chase first reported a position in MLTX in Q4 2022 and has held it in 15 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • JP Morgan Chase held 1,386,422 shares of MoonLake Immunotherapeutics worth $27.6M as of Q2 2026.
  • JP Morgan Chase bought 297,908 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $5.4M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1946 holding.
  • JP Morgan Chase first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 15 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.